Alto Neuroscience (NYSE:ANRO) Stock Price Up 6.6% – Still a Buy?

Alto Neuroscience, Inc. (NYSE:ANRO) rose 6.6% on Tuesday . The stock traded as high as $19.68 and last traded at $19.4420. Approximately 290,064 shares traded hands during trading, an increase of 2% from the average daily volume of 283,774 shares. The stock had previously closed at $18.24.

Analyst Ratings Changes

ANRO has been the topic of several research reports. Jefferies Financial Group restated a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a research report on Monday, March 16th. Chardan Capital restated a “buy” rating and set a $30.00 price target on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Alto Neuroscience in a research report on Wednesday, May 27th. Weiss Ratings raised shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Finally, Robert W. Baird lowered their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Price Performance

The stock has a market capitalization of $749.61 million, a P/E ratio of -8.83 and a beta of 1.22. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. The business’s 50 day moving average price is $22.77 and its 200 day moving average price is $19.44.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). Sell-side analysts forecast that Alto Neuroscience, Inc. will post -3.01 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently modified their holdings of ANRO. Commodore Capital LP purchased a new position in Alto Neuroscience in the fourth quarter worth about $32,453,000. Perceptive Advisors LLC boosted its position in Alto Neuroscience by 1,048.5% in the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after buying an additional 1,629,027 shares during the period. Vestal Point Capital LP raised its position in Alto Neuroscience by 161.6% during the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after purchasing an additional 1,535,000 shares in the last quarter. Spruce Street Capital LP raised its position in Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after purchasing an additional 1,102,366 shares in the last quarter. Finally, Vivo Capital LLC purchased a new position in Alto Neuroscience during the 4th quarter valued at about $18,433,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.